Search

Your search keyword '"T Vandergraesen"' showing total 3 results
Start Over Author "T Vandergraesen"
3 results on '"T Vandergraesen"'

1. Successful transition from paediatric to adult care in sickle cell disease

Author

Sophie Huybrechts, T Vandergraesen, S Diallo, Phu Quoc Lê, Catherine Heijmans, Laurence Dedeken, Alina Ferster, Marie-Agnès Azerad, André Efira, and Ch Devalck

Subjects
Pediatrics, medicine.medical_specialty, medicine.anatomical_structure, Transition (genetics), business.industry, Cell, Medicine, General Medicine, Disease, Adult care, business
Published
2019
Full Text
View/download PDF

3. A case report of serious haemolysis in a glucose-6-phosphate dehydrogenase-deficient COVID-19 patient receiving hydroxychloroquine.

Author

Maillart E, Leemans S, Van Noten H, Vandergraesen T, Mahadeb B, Salaouatchi MT, De Bels D, and Clevenbergh P

Subjects
Aged, Azithromycin therapeutic use, Betacoronavirus genetics, Betacoronavirus isolation & purification, Blood Transfusion, COVID-19, Continuous Renal Replacement Therapy, Drug Therapy, Combination, Enzyme Inhibitors therapeutic use, Haptoglobins analysis, Humans, Hydroxychloroquine therapeutic use, Hypoxia chemically induced, Hypoxia complications, Male, Nasopharynx virology, Pandemics, Respiratory Distress Syndrome complications, Severe acute respiratory syndrome-related coronavirus genetics, Severe acute respiratory syndrome-related coronavirus isolation & purification, SARS-CoV-2, Coronavirus Infections complications, Coronavirus Infections drug therapy, Enzyme Inhibitors adverse effects, Glucosephosphate Dehydrogenase Deficiency complications, Hemolysis, Hydroxychloroquine adverse effects, Pneumonia, Viral complications, Pneumonia, Viral drug therapy
Abstract

While the COVID-19 epidemic occurred since December 2019, as of end April 2020, no treatment has been validated or invalidated by accurate clinical trials. Use of hydroxychloroquine has been popularised on mass media and put forward as a valid treatment option without strong evidence of efficacy. Hydroxychloroquine (HCQ) has its own side effects, some of which are very serious like acute haemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient patients. Side effects may be worse than the disease itself. Belgian national treatment guidelines recommend the use of HCQ in mild to severe COVID-19 disease. As opinions, politics, media and beliefs are governing COVID-19 therapy, performance of randomised controlled blinded clinical trials became difficult. Results of sound clinical trials are eagerly awaited. We report a case of acute haemolysis leading to admission in intensive care unit and renal failure in a patient with uncovered G6PD deficiency.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results